| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total Revenues | $87.0M+1856.7% | $4.4M-93.8% | $71.3M+9.4% | $65.2M+17.9% | $55.3M+12.3% | $49.2M-21.4% | $62.7M+18.7% | $52.8M |
| Total Cost of revenues | $60.4M+1779.4% | $3.2M-83.6% | $19.6M+26.9% | $15.5M+32.9% | $11.7M+0.9% | $11.6M-24.9% | $15.4M+23.6% | $12.4M |
| Gross profit | $72.3M+33.5% | $54.2M+4.8% | $51.7M+4.0% | $49.7M+13.9% | $43.7M+15.8% | $37.7M-20.3% | $47.3M+17.2% | $40.3M |
| Sales and marketing | $47.5M+4.0% | $45.6M-3.6% | $47.3M-5.3% | $50.0M+32.4% | $37.7M+15.9% | $32.6M-24.3% | $43.0M+12.4% | $38.3M |
| General and administrative | $49.7M+63.9% | $30.3M+19.3% | $25.4M-0.4% | $25.5M-0.1% | $25.6M+40.1% | $18.2M+4.5% | $17.5M+27.7% | $13.7M |
| Research and development | $6.6M-48.4% | $12.8M+34.2% | $9.5M+1.9% | $9.3M+17.8% | $7.9M-13.9% | $9.2M-33.1% | $13.7M+67.0% | $8.2M |
| Total operating expenses | $103.7M+16.9% | $88.7M+7.9% | $82.3M-3.0% | $84.8M+19.1% | $71.2M+18.7% | $60.0M-19.1% | $74.2M+23.3% | $60.2M |
| Loss from operations | -$31.4M+9.0% | -$34.6M-13.1% | -$30.6M+13.0% | -$35.1M-27.4% | -$27.6M-23.6% | -$22.3M+17.2% | -$26.9M-35.8% | -$19.8M |
| Interest expense | $8.4M+15.5% | $7.3M+34.3% | $5.4M+27.6% | $4.3M+5.8% | $4.0M-11.1% | $4.5M+22.7% | $3.7M-0.1% | $3.7M |
| Loss on extinguishment of debt | $4.4M | — | — | — | — | — | — | — |
| Other income, net | -$716K+71.9% | -$2.5M+56.0% | -$5.8M-162.8% | -$2.2M-464.9% | -$390K-29.1% | -$302K+80.8% | -$1.6M-373.2% | $575K |
| Net loss | -$39.1M+10.5% | -$43.7M-44.8% | -$30.2M+18.8% | -$37.2M-19.1% | -$31.2M | — | — | — |
| Less: Net loss attributable to non-controlling interest | -$137K-621.1% | -$19K | — | — | — | — | — | — |
| Net loss attributable to Neuronetics stockholders' | -$39.0M+10.8% | -$43.7M-44.8% | -$30.2M+18.8% | -$37.2M-19.1% | -$31.2M-13.6% | -$27.5M+5.5% | -$29.0M-20.5% | -$24.1M |
| Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders' | -$590.00+57.2% | -$1380.00-31.4% | -$1050.00+23.9% | -$1380.00-13.1% | -$1220.00+16.4% | -$1460.00+7.6% | -$1580.00 | — |
| Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders' | -$590.00+57.2% | -$1380.00-31.4% | -$1050.00+23.9% | -$1380.00-13.1% | -$1220.00+16.4% | -$1460.00+7.6% | -$1580.00 | — |
| Weighted average common shares outstanding, basic (in shares) | 66.0M+107.8% | 31.7M+10.7% | 28.7M+6.5% | 26.9M+5.6% | 25.5M+35.3% | 18.8M+2.5% | 18.4M | — |
| Weighted average common shares outstanding, diluted (in shares) | 66.0M+107.8% | 31.7M+10.7% | 28.7M+6.5% | 26.9M+5.6% | 25.5M+35.3% | 18.8M+2.5% | 18.4M | — |
| Products and Other | ||||||||
| Services | ||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.